Eli Lilly, Food and Drug Administration
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active ...
Morgan Stanley noted that two compounding groups – the Outsourcing Facilities Association and North American Custom Laboratories – filed a ...
As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...
Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.
Eli Lilly ( LLY) announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the ...
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...
The move positions Lilly as a competitive alternative to compounded weight-loss drugs, especially as the FDA cracks down ... Cardiometabolic Health at Eli Lilly and Company, told Health.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback